Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Kazia Therapeutics is a clinical-stage oncology-focused biopharmaceutical company developing paxalisib (GDC-0084), a brain-penetrant PI3K/mTOR inhibitor for glioblastoma and brain metastases. The company has no commercial revenue and operates as a pre-revenue R&D entity dependent on clinical trial outcomes and partnership agreements. With negative operating cash flow of approximately $15-20M annually and a current ratio of 0.35, the company faces near-term liquidity constraints requiring capital raises or strategic transactions.
Kazia operates a classic biotech development model: advance drug candidates through clinical trials (Phase II/III), then either commercialize independently or out-license to larger pharmaceutical partners for milestone payments and royalties. Paxalisib targets high unmet need in brain cancers where blood-brain barrier penetration is critical. Value creation depends entirely on clinical trial success, regulatory approval probability, and partnership economics. The company has no pricing power until post-approval and faces binary risk events at each clinical milestone.
Paxalisib clinical trial data releases and interim analysis results from ongoing glioblastoma studies
FDA regulatory interactions including Fast Track, Orphan Drug, or Breakthrough Therapy designations
Partnership announcements or licensing deals with major pharmaceutical companies for development/commercialization rights
Capital raising events including equity offerings, warrant exercises, or debt financing that impact dilution and runway
Competitive landscape changes in glioblastoma treatment including approvals of rival therapies or trial failures
Binary clinical trial risk - single late-stage trial failure could render paxalisib program worthless and eliminate primary asset value
Regulatory approval uncertainty in oncology where FDA requires robust survival benefit data and safety profiles in already-treated patient populations
Reimbursement pressure in oncology as payers increasingly scrutinize cost-effectiveness of specialty drugs, particularly in rare indications like glioblastoma
Competitive therapies in glioblastoma including Novocure's tumor treating fields, Bristol Myers Squibb's Opdivo combinations, and other PI3K inhibitors in development
Larger pharmaceutical companies with superior resources could advance competing brain-penetrant oncology assets faster or acquire competitive programs
Critical liquidity risk with current ratio of 0.35 indicating insufficient current assets to cover near-term obligations without additional financing
Dilution risk from necessary equity raises given negative $15-20M annual cash burn and limited non-dilutive funding options
Going concern risk if unable to secure financing before cash depletion, potentially forcing unfavorable partnership terms or asset sales
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, capital markets access for funding is highly sensitive to risk appetite and biotech sector sentiment during economic downturns. Patient enrollment can be marginally affected by healthcare utilization patterns in recessions.
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (8-10+ years until potential commercialization). Higher rates also reduce speculative capital flowing into pre-revenue biotechs and increase opportunity cost versus risk-free assets. Minimal direct business impact as the company carries negligible debt, but equity financing becomes more expensive and dilutive when rates rise.
Minimal direct credit exposure as the company has negative debt-to-equity (-0.05) and operates without meaningful debt obligations. However, credit market conditions indirectly affect ability to secure venture debt or convertible financing as bridge capital between equity raises.
growth - Attracts speculative biotech investors seeking asymmetric risk/reward from clinical trial catalysts. Typical holders include specialized healthcare hedge funds, biotech-focused venture investors, and retail traders seeking binary event-driven opportunities. Not suitable for value or income investors given pre-revenue status and high cash burn.
high - Clinical-stage biotechs with single-asset concentration exhibit extreme volatility around data releases (30-70% single-day moves common). Stock trades on sentiment, sector rotation, and binary trial outcomes rather than fundamental cash flows. Estimated beta >2.0 relative to broader biotech indices with frequent 20%+ monthly swings.
